HC Wainwright & Co. Initiates Coverage On Odyssey Therapeutics with Buy Rating, Announces Price Target of $44
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsInitiationPrice Target
HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Odyssey Therapeutics (NASDAQ:ODTX) with a Buy rating and announces Price Target of $44.
HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Odyssey Therapeutics (NASDAQ:ODTX) with a Buy rating and announces Price Target of $44.